W Jean Dodds1* and Jon P Kimball2
Objective: Although the development of novel, potent flea and tick preventives began more than 20 years ago, with collars, spot-on topical, and tablets/chews, adverse events associated with their use have recently escalated since these reactions report were reviewed. Adverse events are believed to be grossly underreported, and 3 Class Action lawsuits have been filed in North America.
Materials and methods: The present report updates the previously published Jake Survey conducted in 2018 and published in 2020, to include US Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) adverse events. Along with European Medicines Agency (EMA) data through spring 2021.
Conclusion: Updated results from the USA and European Union indicate a notable increase in the number of particularly serious adverse events reported for the flea and tick preventives including seizures, behavioural aggression, and death. The actual number of adverse incidents is likely much higher than those reported to regulatory agencies.
